Catabasis Pharma (CATB) Tops Q3 EPS by 11c
- S&P 500 closes higher to secure strongest Q1 since 2019
- UBS sees 5 warnings signals on semiconductor chip stocks
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- Reddit (RDDT) stock continues to slide as short-sellers eye stock
- Estée Lauder (EL) climbs as BofA upgrades to Buy on profit recovery expectations
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- Discover Financial Services (DFS) Announces CEO Resignation
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Timken (TKR) Appoints Tarak Mehta as New CEO
Catabasis Pharmaceuticals Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights
November 10, 2016 4:10 PM EST-- Enrollment Complete for MoveDMD® Phase 2 Trial of Edasalonexent, a Potential Disease-Modifying Treatment for Duchenne Muscular Dystrophy (DMD) --
-- Expanding Rare Disease Pipeline with CAT-5571, a Potential Treatment for Cystic Fibrosis --
-- Investor Day Scheduled for November 17 --
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB), a... More